Population-level implications of the Israeli booster campaign to curtail COVID-19 resurgence

Author:

Gavish Nir1ORCID,Yaari Rami2ORCID,Huppert Amit23ORCID,Katriel Guy4ORCID

Affiliation:

1. Faculty of Mathematics, Technion Israel Institute of Technology, Haifa 32000, Israel.

2. Bio-statistical and Bio-mathematical Unit, Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical Center, Ramat Gan 52621, Israel.

3. School of Public Health, Tel Aviv University, Tel Aviv-Yafo 6997801, Israel.

4. Department of Applied Mathematics, ORT Braude College of Engineering, Karmiel 2161002, Israel.

Abstract

Israel was one of the first countries to administer mass vaccination against severe acute respiratory syndrome coronavirus 2. Consequently, it was among the first countries to experience substantial breakthrough infections due to the waning of vaccine-induced immunity, which led to a resurgence of the epidemic. In response, Israel launched a booster campaign to mitigate the outbreak and was the first country to do so. Israel’s success in curtailing the Delta resurgence while imposing only mild nonpharmaceutical interventions influenced the decision of many countries to initiate a booster campaign. By constructing a detailed mathematical model and calibrating it to the Israeli data, we extend the understanding of the impact of the booster campaign from the individual to the population level. We used the calibrated model to explore counterfactual scenarios in which the booster vaccination campaign is altered by changing the eligibility criteria or the start time of the campaign and to assess the direct and indirect effects in the different scenarios. The results point to the vast benefits of vaccinating younger age groups that are not at a high risk of developing severe disease but play an important role in transmission. We further show that, when the epidemic is exponentially growing, the success of the booster campaign is highly sensitive to the timing of its initiation. Hence, a rapid response is an important factor in reducing disease burden using booster vaccination.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference25 articles.

1. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting;Dagan N.;N. Engl. J. Med.,2021

2. E. J. Haas F. J. Angulo J. M. McLaughlin E. Anis S. R. Singer F. Khan N. Brooks M. Smaja G. Mircus K. Pan J. Southern D. L. Swerdlow L. Jodar Y. Levy S. Alroy-Preis Nationwide vaccination campaign with BNT162b2 in Israel demonstrates high vaccine effectiveness and marked declines in incidence of SARS-CoV-2 infections and Covid-19 cases hospitalizations and deaths (2021).

3. Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel;Goldberg Y.;medRxiv,2021

4. Waning immunity after the BNT162b2 vaccine in Israel;Goldberg Y.;N. Engl. J. Med.,2021

5. Protection of BNT162b2 vaccine booster against Covid-19 in Israel;Bar-On Y. M.;N. Engl. J. Med.,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3